$QURE

Schall Law Firm initiates securities fraud class action against uniQure ($QURE) over alleged false FDA approval statements and misleading BLA timelines.

Hagens Berman investigates $QURE for allegedly misrepresenting FDA interactions on AMT-130 gene therapy. Stock crashed 49% November 3 after FDA disagreement revealed.

uniQure stock plunged 49% after FDA disagreement on gene therapy trial design. Investors with losses eligible to join class action lawsuit by April 2026.

uniQure faces securities fraud lawsuit after FDA rejection of AMT-130 data triggers 49% stock plunge from $67.69 to $34.29 on November 3, 2025.

Pomerantz Law Firm filed class action against $AMC over alleged securities fraud regarding APE preferred equity units excluded from special dividend. Investors must act by April 20, 2026.

Pomerantz Law Firm filed class action against $QURE after 49% stock decline following FDA concerns over gene therapy study data adequacy.

Rosen Law Firm initiates securities class action against $TCOM for allegedly understating regulatory risks from monopolistic practices. May 11 deadline for investors.

Rosen Law Firm alerts $QURE investors with losses exceeding $100K to meet April 13 deadline in securities class action over alleged FDA approval status misrepresentation.

Rosen Law Firm urges Inovio investors with $100K+ losses to file by April 7 deadline in securities class action alleging false manufacturing and regulatory statements.

uniQure faces securities investigation after FDA publicly disputed the company's claims about regulatory guidance for gene therapy candidate AMT-130, with April 2026 deadline for investor class action.

Securities class action filed against $QURE for alleged misrepresentation regarding Pivotal Study design and FDA approval timeline for Huntington's disease treatment.

uniQure faces securities class action over alleged FDA disclosure failures; investors have until April 13, 2026, to join litigation seeking damages.

uniQure's stock plummeted 49% after FDA rejected its AMT-130 drug candidate; securities fraud lawsuit filed for alleged failure to disclose approval risks during September-October 2025.

$QURE plummeted 49% after FDA feedback on AMT-130 gene therapy. Pomerantz Law Firm filed class action lawsuit; investor deadline April 13, 2026.

uniQure shares collapsed 49% after FDA signaled Phase I/II data insufficient for AMT-130 approval, prompting investors to file class action lawsuit.

Schall Law Firm seeks lead plaintiffs in class action against $QURE for alleged false statements regarding FDA approval timeline and BLA submission misrepresentations.

Rosen Law Firm urges $QURE investors to join securities lawsuit alleging misrepresentation of Pivotal Study design and BLA timeline delays. Lead plaintiff deadline: April 13, 2026.

Hagens Berman investigates $QURE over FDA allegations of misrepresented gene therapy data and manipulated study design. Stock tumbled 49% following November 3 FDA rebuttal.

The Gross Law Firm filed a class action lawsuit against uniQure N.V. for allegedly making false statements about FDA approval and BLA timeline prospects.

uniQure faces securities lawsuit after FDA rejected AMT-130 drug candidate data adequacy. Stock plunged 49% following disclosure. Lead plaintiff deadline April 13, 2026.